These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

450 related items for PubMed ID: 30122225

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Optimization of the efflux ratio and permeability of covalent irreversible BTK inhibitors.
    Qiu H, Liu-Bujalski L, Caldwell RD, Viacava Follis A, Gardberg A, Goutopoulos A, Grenningloh R, Head J, Johnson T, Jones CCV, Jones R, Mochalkin I, Morandi F, Neagu C, Potnick J, Sherer B.
    Bioorg Med Chem Lett; 2018 Nov 01; 28(20):3307-3311. PubMed ID: 30243592
    [Abstract] [Full Text] [Related]

  • 3. Discovery of potent and selective reversible Bruton's tyrosine kinase inhibitors.
    Qiu H, Ali Z, Bender A, Caldwell R, Chen YY, Fang Z, Gardberg A, Glaser N, Goettsche A, Goutopoulos A, Grenningloh R, Hanschke B, Head J, Johnson T, Jones C, Jones R, Kulkarni S, Maurer C, Morandi F, Neagu C, Poetzsch S, Potnick J, Schmidt R, Roe K, Viacava Follis A, Wing C, Zhu X, Sherer B.
    Bioorg Med Chem; 2021 Jun 15; 40():116163. PubMed ID: 33932711
    [Abstract] [Full Text] [Related]

  • 4. Conversion of carbazole carboxamide based reversible inhibitors of Bruton's tyrosine kinase (BTK) into potent, selective irreversible inhibitors in the carbazole, tetrahydrocarbazole, and a new 2,3-dimethylindole series.
    Liu Q, Batt DG, Chaudhry C, Lippy JS, Pattoli MA, Surti N, Xu S, Carter PH, Burke JR, Tino JA.
    Bioorg Med Chem Lett; 2018 Oct 01; 28(18):3080-3084. PubMed ID: 30097367
    [Abstract] [Full Text] [Related]

  • 5. Discovery of 5-Phenoxy-2-aminopyridine Derivatives as Potent and Selective Irreversible Inhibitors of Bruton's Tyrosine Kinase.
    Lee E, Cho H, Lee DK, Ha J, Choi BJ, Jeong JH, Ryu JH, Kang JS, Jeon R.
    Int J Mol Sci; 2020 Oct 28; 21(21):. PubMed ID: 33126415
    [Abstract] [Full Text] [Related]

  • 6. Discovery of Covalent Bruton's Tyrosine Kinase Inhibitors with Decreased CYP2C8 Inhibitory Activity.
    Qiu H, Ali Z, Bowlan J, Caldwell R, Gardberg A, Glaser N, Goutopoulos A, Head J, Johnson T, Maurer C, Georgi K, Grenningloh R, Fang Z, Morandi F, Rohdich F, Schmidt R, Follis AV, Sherer B.
    ChemMedChem; 2021 Dec 14; 16(24):3653-3662. PubMed ID: 34582626
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Discovery and structure-activity relationship of novel diphenylthiazole derivatives as BTK inhibitor with potent activity against B cell lymphoma cell lines.
    Guo X, Yang D, Fan Z, Zhang N, Zhao B, Huang C, Wang F, Ma R, Meng M, Deng Y.
    Eur J Med Chem; 2019 Sep 15; 178():767-781. PubMed ID: 31234030
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Discovery and Biological evaluation of pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione derivatives as potent Bruton's tyrosine kinase inhibitors.
    Diao Y, Fang X, Song P, Lai M, Tong L, Hao Y, Dou D, Liu Y, Ding J, Zhao Z, Xie H, Li H.
    Bioorg Med Chem; 2019 Aug 01; 27(15):3390-3395. PubMed ID: 31221612
    [Abstract] [Full Text] [Related]

  • 13. Discovery of potent and highly selective covalent inhibitors of Bruton's tyrosine kinase bearing triazine scaffold.
    Teng Y, Lu X, Xiao M, Li Z, Zou Y, Ren S, Cheng Y, Luo G, Xiang H.
    Eur J Med Chem; 2020 Aug 01; 199():112339. PubMed ID: 32402933
    [Abstract] [Full Text] [Related]

  • 14. Optimization of a novel piperazinone series as potent selective peripheral covalent BTK inhibitors.
    Ma B, Metrick CM, Gu C, Hoemberger M, Bajrami B, Bame E, Huang J, Mingueneau M, Murugan P, Santoro JC, Tang H, Wang T, Hopkins BT.
    Bioorg Med Chem Lett; 2022 Mar 15; 60():128549. PubMed ID: 35041943
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. HZ-A-005, a potent, selective, and covalent Bruton's tyrosine kinase inhibitor in preclinical development.
    Huang W, Wang S, Zhang Z, Zhang C, Zeng S, Liang M, Shen Z, Liu X.
    Bioorg Chem; 2020 Dec 15; 105():104377. PubMed ID: 33091668
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.